Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Targeted oncology

• Publication date

  2009-04-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11523-009-0106-0PMID 19373440PMCID PMC3193279
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

  2023cited by this paper
• Amendment history : Corrigendum ( November 2013 ) An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

  2018cited by this paper
• Cardiotoxicity Associated with the Tyrosine Kinase Inhibitor Sunitinib

  2013cited by this paper
• Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment

  2009cited by this paper
• Hemostatic complications of angiogenesis inhibitors in cancer patients

  2008cited by this paper
• Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.

  2008cited by this paper
• Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.

  2008cited by this paper
• Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

  2008cited by this paper
• Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation.

  2008cited by this paper
• Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?

  2008cited by this paper
• VEGF-targeted therapy: mechanisms of anti-tumour activity

  2008cited by this paper
• Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.

  2008cited by this paper
• Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

  2008cited by this paper
• Unlocking the potential of bile acids in synthesis, supramolecular/materials chemistry and nanoscience.

  2008cited by this paper
• Heart failure associated with sunitinib malate

  2008cited by this paper
• Cardiovascular toxicity of new agents.

  2008cited by this paper
• Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

  2007cited by this paper
• In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

  2007cited by this paper
• Phase I Evaluation of CDP791, a PEGylated Di-Fab′ Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2

  2007cited by this paper
• Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.

  2007cited by this paper
• Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

  2007cited by this paper
• Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

  2007cited by this paper
• An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.

  2007cited by this paper
• Mechanisms of adverse effects of anti-VEGF therapy for cancer

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Ambulatory blood-pressure monitoring.

  2006cited by this paper
• VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.

  2006cited by this paper
• Reversible posterior leukoencephalopathy syndrome and bevacizumab.

  2006cited by this paper
• Roles of Nitric Oxide Synthase Inhibition and Vascular Endothelial Growth Factor Receptor-2 Inhibition on Vascular Morphology and Function in an In vivo Model of Pancreatic Cancer

  2006cited by this paper
• Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.

  2006cited by this paper
• Reversible posterior leukoencephalopathy syndrome and bevacizumab.

  2006cited by this paper
• Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

  2006cited by this paper
• Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer.

  2006cited by this paper
• Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors

  2006cited by this paper
• Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Bevacizumab combination therapy in recurrent, platinum‐refractory, epithelial ovarian carcinoma

  2006cited by this paper
• Thalidomide and lenalidomide in the treatment of multiple myeloma.

  2006cited by this paper
• The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.

  2006cited by this paper
• Mechanisms of hypertension associated with BAY 43-9006.

  2006cited by this paper
• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

  2006cited by this paper
• Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.

  2006cited by this paper
• Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?

  2006cited by this paper
• Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC).

  2006cited by this paper
• Angiogenesis inhibitors and hypertension: an emerging issue.

  2006cited by this paper
• Angiogenesis in life, disease and medicine

  2005cited by this paper
• Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate.

  2005cited by this paper
• Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

  2005cited by this paper
• Angiogenesis and lung cancer: prognostic and therapeutic implications.

  2005cited by this paper
• Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers.

  2005cited by this paper
• Age-Related Changes in Vascular Endothelial Growth Factor Dependency and Angiopoietin-1–Induced Plasticity of Adult Blood Vessels

  2004cited by this paper
• Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

  2004cited by this paper
• Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas

  2004cited by this paper
• Measuring blood pressure accurately: new and persistent challenges.

  2003cited by this paper
• A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.

  2003cited by this paper
• Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis

  2003cited by this paper
• Endostatin: are the 2 years up yet?

  2002cited by this paper
• Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.

  2000cited by this paper
• Tumor angiogenesis: past, present and the near future.

  2000cited by this paper
• Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases

  2000cited by this paper
• Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

  1999cited by this paper
• Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.

  1997cited by this paper
• Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy.

  1996cited by this paper
• Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.

  1996cited by this paper
• Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

  1993cited by this paper
• Human blood pressure determination by sphygmomanometry.

  1993cited by this paper
• Ambulatory blood pressure monitoring.

  1985cited by this paper
• The vascularization of tumors.

  1976cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971cited by this paper
• The Emerging Issue

  1910cited by this paper

• Cardiovascular signaling proteins as predictors of the cardiac effects of doxorubicin treatment in children with acute lymphoblastic leukemia.

  2026cites this paper
• The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup.

  2025cites this paper
• Immuun- en targeted therapie

  2021cites this paper
• Challenges and Management of Acute Coronary Syndrome in Cancer Patients

  2021cites this paper
• Fatal diffuse alveolar haemorrhage mimicking acute exacerbation in idiopathic pulmonary fibrosis treated with nintedanib

  2017cites this paper
• Clinical Development of VEGF Signaling Pathway Inhibitors in Childhood Solid Tumors

  2017cites this paper
• Chapter 10 – Cardiovascular Complications from Cancer Therapy: Hypertension–Focus on Vascular Endothelial Growth Factor Inhibitors

  2016cites this paper
• Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats

  2016cites this paper
• Hypertension induced by chemotherapeutic and immunosuppresive agents: a new challenge.

  2015cites this paper
• Adverse Gastrointestinal Events with Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Nested Case–Control Study

  2014cites this paper
• Systematic Review of the Risk of Adverse Outcomes Associated with Vascular Endothelial Growth Factor Inhibitors for the Treatment of Cancer

  2014cites this paper
• Antiangiogenic Drugs and Cardiogenic Shock: A Case Report

  2014cites this paper
• Erratum to: Adverse Gastrointestinal Events with Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Nested Case–Control Study

  2014cites this paper
• Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome.

  2014cites this paper
• Complications of Subspecialty Ophthalmic Care: Systemic Complications from the Intravitreal Administration of Agents that Target the Vascular Endothelial Growth Factor Pathway

  2014cites this paper
• Nephrotoxicity of recent anti-cancer agents

  2013cites this paper
• Systemic effects of intravitreal vascular endothelial growth factor inhibitors

  2013cites this paper
• Immuno- en targeted therapie

  2013cites this paper
• VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.

  2012cites this paper
• VEGF remains an interesting target in advanced pancreas cancer ( APCA ) : results of a multi-institutional phase II study of bevacizumab , gemcitabine , and infusional 5-fl uorouracil in patients with APCA

  2012cites this paper
• Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review.

  2012cites this paper
• Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study

  2012cites this paper
• NEPHROTOXICITY OF ANTICANCER DRUGS – AN UNDERESTIMATED PROBLEM?

  2011cites this paper
• Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.

  2011cites this paper
• Antiangiogenic Agents for the Treatment of Nonsmall Cell Lung Cancer: Characterizing the Molecular Basis for Serious Adverse Events

  2011cites this paper
• Therapeutic advances in women's cancers.

  2011cites this paper
• Hypertension Induced by VEGF Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker

  2011cites this paper
• Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors

  2010cites this paper
• Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.

  2010cites this paper
• Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.

  2010cites this paper
• Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

  2010cites this paper
• Hypertension and renal disease during anti-cancer therapies

  year unknowncites this paper